Ocular cicatricial pemphigoid: Methotrexate as an initial treatment?
Reumatol Clin (Engl Ed)
; 18(1): 30-32, 2022 Jan.
Article
en En
| MEDLINE
| ID: mdl-34088654
ABSTRACT
OBJECTIVE:
To analyse the clinical/epidemiological data, the management and the treatments established in patients with Ocular Cicatricial Pemphigoid (OCP) in a Rheumatology Service. MATERIAL ANDMETHODS:
Review of clinical histories of patients with OCP referred by ophthalmology between 2008 and 2019.RESULTS:
In our series of 27 patients, 67% were diagnosed and referred in the last 2 years. Most in Foster stage 1. Of the patients, 18.5% presented associated Sjogren's syndrome, with poor progression 88.8% received Methotrexate, 74% used it as monotherapy and 66% continued with said treatment up to the end. Eighteen point five percent had to combine or rotate therapies, the drugs used were mycophenolate, azathioprine, cyclophosphamide, sirolimus, etanercept, rituximab 29% used steroids. Only in 2 eyes was stage progression observed. There were no serious adverse events, and 37% had mild adverse events.CONCLUSION:
Starting immunosuppressive therapy early is essential, methotrexate being a good initial alternative in our experience, and treatment must be escalated in line with disease progression.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Metotrexato
/
Penfigoide Benigno de la Membrana Mucosa
Tipo de estudio:
Diagnostic_studies
Límite:
Humans
Idioma:
En
Revista:
Reumatol Clin (Engl Ed)
Año:
2022
Tipo del documento:
Article